Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06136364 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 18, 2023 (before its estimated August 15, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Trial Details
NCT Number NCT06136364
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Conditions T-lymphoblastic Lymphoma, T-ALL
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov